Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 5;8:8623. doi: 10.1038/s41598-018-26918-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Evaluation of the EAMG rat model. Before immunization, the weight of the normal group rats remained stable, and the rats exhibited sustained growth. The model group rats grew slowly during the week of the first immunization, and their weights tended to be stable and thus did not increase after the second booster immunization (a). Before QJJL treatment, 8 rats in the model group died due to severe myasthenia gravis (MG) symptoms, and 54 rats remained alive. During the second week after the first immunization, some of the rats in the model group began to display symptoms of MG and were found to have Lennon scores up to 0.5. With the passage of time, the MG symptoms displayed by the rats in the model group gradually worsened. At 1 week after the last immunization, virtually all of the model group rats had a Lennon score of 0.5 or greater. Specifically, 94.44% of the rats had a score of 0.5 or higher, and 75.93% of the rats had a score of 1.0 or higher. The rats in the blank control group had a score of 0 (b). The degree of electrical attenuation was detected by repetitive nerve stimulation (RNS) in both the normal and model groups at one week after the third immunization. The percentage change between the first and fifth action potentials was the attenuation value D, and a percentage change > 10% was considered positive (c,d).